Holen Sie sich die Stockscreener-App
1.74
1.16%
0.02
Vorhandelsmarkt:
1.76
0.02
+1.15%
Schlusskurs vom Vortag:
$1.72
Offen:
$1.73
24-Stunden-Volumen:
706.93K
Relative Volume:
0.77
Marktkapitalisierung:
$130.95M
Einnahmen:
$302.48M
Nettoeinkommen (Verlust:
$-265.26M
KGV:
-0.4682
EPS:
-3.716
Netto-Cashflow:
$-2.76M
1W Leistung:
-3.33%
1M Leistung:
+9.43%
6M Leistung:
+58.90%
1J Leistung:
-39.16%
1-Tages-Spanne:
$1.71
$1.76
1-Wochen-Bereich:
$1.71
$1.89
52-Wochen-Spanne:
$0.9551
$3.615
Health Catalyst Inc Stock (HCAT) Company Profile
Firmenname
Health Catalyst Inc
Sektor
Branche
Telefon
801-708-6800
Adresse
10897 SOUTH RIVER FRONT PARKWAY, #300, SOUTH JORDAN
Compare HCAT vs VEEV, TEM, BTSG, TXG, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCAT
Health Catalyst Inc
|
1.74 | 130.95M | 302.48M | -265.26M | -2.76M | -3.716 |
VEEV
Veeva Systems Inc
|
274.84 | 44.50B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
82.24 | 14.93B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
56.02 | 11.08B | 13.65B | 169.86M | 412.12M | 1.0758 |
TXG
10 X Genomics Inc
|
84.11 | 10.96B | 638.78M | -22.66M | 122.18M | -0.1744 |
HNGE
Hinge Health Inc
|
91.98 | 7.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
Health Catalyst Inc Stock (HCAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-08-27 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-08-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-01-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2024-01-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-11-13 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-04-20 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-04-12 | Eingeleitet | Stephens | Equal-Weight |
| 2023-04-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-05 | Herabstufung | Stifel | Buy → Hold |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-03-17 | Hochstufung | Jefferies | Hold → Buy |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-10-14 | Eingeleitet | BTIG Research | Buy |
| 2021-04-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-12-08 | Eingeleitet | Berenberg | Buy |
| 2020-07-14 | Eingeleitet | Citigroup | Buy |
| 2020-06-18 | Eingeleitet | Stifel | Buy |
| 2020-06-15 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-05-15 | Eingeleitet | Guggenheim | Buy |
| 2020-04-21 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-04-13 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-12-20 | Eingeleitet | Raymond James | Strong Buy |
| 2019-10-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-19 | Eingeleitet | Goldman | Buy |
| 2019-08-19 | Eingeleitet | JP Morgan | Overweight |
| 2019-08-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-19 | Eingeleitet | SunTrust | Buy |
| 2019-08-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Health Catalyst Inc Aktie (HCAT) Neueste Nachrichten
Europe Clinical Data Analytics Market Outlook 2026-2033 | AI, Cloud Deployment and Data-Driven Healthcare Adoption Accelerate Across the Region - GlobeNewswire Inc.
Wells Fargo raises Health Catalyst price target to $1.75 - scanx.trade
Simeon Kohl Bought 118% More Shares In Health Catalyst - webull.com
Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks - Yahoo Finance
Health Catalyst stock trades near lows as small-cap sentiment weakens - AD HOC NEWS
Health Catalyst Q2FY26 Results: Revenue beats guidance, debt retired - scanx.trade
Health Catalyst Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Health Catalyst CEO Kohl Simeon Granted 2.75M Shares in Equity Award and Acquires Additional Stock - kalkinemedia.com
Health Catalyst Adds Tami Reller to Board for Growth - The Globe and Mail
Health Catalyst reports inducement awards - Medical Buyer
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Health Catalyst appoints Tami Reller to board of directors By Investing.com - Investing.com Australia
Health Catalyst appoints Tami Reller to board of directors - Investing.com
Health Catalyst appoints Tami Reller to board a... - Pluang
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller - PR Newswire
Health Catalyst Appoints Simeon Kohl As CEO And President - Pulse 2.0
Health Catalyst CEO Albert Benjamin Forfeits 35,244 Shares at $1.67, Retains 1.39 Million Shares - Kalkine Media
Mandatory tax sale by Health Catalyst (HCAT) CEO - Stock Titan
Planned $59K stock sale at Health Catalyst (NASDAQ: HCAT) - Stock Titan
Health Catalyst appoints new CEO - healthcaredive.com
The Escalator: Inizio, Health Catalyst, Eversana and more - Medical Marketing and Media
Canaccord Genuity Sticks to Its Hold Rating for Health Catalyst (HCAT) - The Globe and Mail
Palogic Value Management Increases Activist Stake to 7.1% in Health Catalyst (NASDAQ: HCAT) - Kalkine Media
Palogic Value Management Secures 7.1% Activist Stake in Health Catalyst (NASDAQ: HCAT) - Kalkine Media
Health Catalyst appoints Simeon Kohl as new CEO - The Globe and Mail
symbol__ Stock Quote Price and Forecast - cnn.com
Health Catalyst Names Simeon Kohl As CEO And President And Ben Albert To Become Chief Business Officer - Pulse 2.0
Investor group asks for clearer plan at Health Catalyst (NASDAQ: HCAT) - Stock Titan
Health Catalyst taps new CEO - modernhealthcare.com
Health Catalyst, Inc. Announces CEO Changes - marketscreener.com
Health Catalyst Appoints Simeon Kohl as CEO, Ben Albert Steps Down - Minichart
Health Catalyst names Simeon Kohl as new CEO By Investing.com - Investing.com Canada
The Next Healthcare Catalyst Hunt Is On — Why Knight Therapeutics, Inc. (TSX:GUD) Could Draw Attention - kalkine.ca
Health Catalyst names Simeon Kohl as new CEO - Investing.com
Health Catalyst gets a new chief after he led a healthcare company through a roughly $670 million sale. - Stock Titan
The Next Healthcare Catalyst Hunt Is On — Why HLS Therapeutics, Inc. (HLS) Could Draw Attention - kalkine.ca
Health Catalyst Grants Insider Julie Larson-Green 9,766 Shares at No Cost (NASDAQ: HCAT) - Kalkine Media
Health Catalyst | 4: Statement of changes in beneficial ownership of securities-Officer Alger Jason - Moomoo
Health Catalyst | 4: Statement of changes in beneficial ownership of securities-Director Larson-Green Julie - Moomoo
Health Catalyst (HCAT) CEO offloads 321 shares to cover taxes - Stock Titan
Health Catalyst (HCAT) CFO sells shares to cover RSU taxes - Stock Titan
Equity grant lifts Health Catalyst (HCAT) director to 185K shares - Stock Titan
Tax-driven stock sale by Health Catalyst (HCAT) legal chief - Stock Titan
Health Catalyst (NASDAQ: HCAT) officer schedules new stock sale after June trades - Stock Titan
Health Catalyst (HCAT) insider plans $30,618.80 stock sale - Stock Titan
Health Catalyst (NASDAQ: HCAT) executive lines up stock sale; size and timing inside - Stock Titan
Health Catalyst to Participate in Upcoming Investor Conference - The Manila Times
Health Catalyst to present at Wells Fargo healthcare conference - scanx.trade
Health Catalyst Market Sentiment - Benzinga España
Health Catalyst Inc (HCAT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Investors Are Hunting for the Next Healthcare Catalyst: Could HLS Therapeutics, Inc (HLS) Deliver? - kalkine.ca
Finanzdaten der Health Catalyst Inc-Aktie (HCAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
2.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):